CD274 and ovarian carcinoma: The KEYNOTE-028 (NCT02054806) is a multicohort Phase Ib clinical trial that assessed the safety and antitumor activity of pembrolizumab in 26 patients with advanced PD-L1 positive ovarian cancer.